speaker-image

David Lubner

speaker-image

Lubner served as EVP and CFO of Ra Pharmaceuticals Inc., which was acquired by UCB in April, 2020. Previously, he was a member of the senior management teams of Tetraphase Pharmaceuticals Inc., PharMetrics Inc., and ProScript. 

  • October 2020

Added to: Gemini Therapeutics - Cambridge, MA

Gemini Therapeutics is a clinical stage precision medicine company developing innovative treatments for age-related macular degeneration and linked ocular disorders that are matched to specific genetic mutations.

  • October 2020

Added to: Dyne Therapeutics - Cambridge, MA

Dyne Therapeutics provides therapies for patients with serious muscle diseases. Their platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle to restore muscle health.